Clinical Trials

Cognitive Impairment Associated with SCHIZOPHRENIA (CIAS)

Luvadaxistat (NBI-1065844/TAK-831) was developed by Takeda Pharmaceutical Company Limited for the treatment of schizophrenia and has completed several Phase I trials in healthy participants. In the Phase II INTERACT study of adults with negative and cognitive symptoms of schizophrenia, luvadaxistat met secondary endpoints of cognitive assessment. Neurocrine Biosciences plans to initiate a Phase II study of luvadaxistat in adults with cognitive impairment associated with schizophrenia (CIAS) in 2021 designed to replicate the signal of cognitive improvement seen in the INTERACT study.